ADXN Profile
Addex Therapeutics Ltd, a development-stage biopharmaceutical company based in Switzerland, is dedicated to discovering, developing, and commercializing small-molecule pharmaceutical products targeting central nervous system (CNS) disorders. The company's primary focus is on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors, which play a crucial role in various physiological processes and disease states. By targeting these receptors, Addex aims to develop innovative therapies that can significantly improve patient outcomes.
The company's lead programs include Dipraglurant, an investigational drug designed for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia. Dipraglurant is currently in clinical development and holds promise for addressing the debilitating motor complications associated with Parkinson's disease. Additionally, Addex is advancing ADX71149, a novel therapeutic candidate for epilepsy and other undisclosed CNS disorders. This compound is being developed in collaboration with industry partners and has shown potential in preclinical and clinical studies.
Addex Therapeutics is also working on GABAB PAM, a positive allosteric modulator of the GABAB receptor, which is being investigated for its potential in treating addiction. The company's robust pipeline reflects its commitment to addressing a wide range of CNS disorders through innovative approaches. Addex has established several strategic partnerships, including license and collaboration agreements with Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot-Marie-Tooth Association, to support the development and commercialization of its therapeutic candidates.
Formerly known as Addex Pharmaceuticals Ltd, the company rebranded to Addex Therapeutics Ltd in March 2012 to better reflect its focus on therapeutic development. Founded in 2002 and headquartered in Geneva, Switzerland, Addex Therapeutics continues to leverage its expertise in allosteric modulation to advance its pipeline and bring novel treatments to market. The company's strategic collaborations and cutting-edge research underscore its dedication to transforming the lives of patients with CNS disorders.
|
